Skip to main content
. 2020 Oct 3;12(10):2855. doi: 10.3390/cancers12102855

Figure 1.

Figure 1

Regulatory timeline of approvals in advanced prostate cancer therapies. DDR+: DNA damage response genes mutated; mHSPC: metastatic hormone-sensitive prostate cancer; mCRPC: metastatic castration-resistant prostate cancer; nmCRPC: nonmetastatic castration-resistant prostate cancer; post-doc: post-docetaxel; pre-doc: pre-docetaxel.